MEDP vs. UTHR: Medpace vs. United Therapeutics Stock Comparison

November 11, 2026

How do Medpace (MEDP) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Medpace (MEDP) and United Therapeutics (UTHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while UTHR is classified in Biotechnology.

Company profile comparison for Medpace (MEDP) and United Therapeutics (UTHR)
Profile Item	MEDP	UTHR
Name	Medpace Holdings, Inc.	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	18.27 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	August 11, 2016	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

MEDP

UTHR

GSPC

Medpace (MEDP) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Medpace (MEDP) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Medpace (MEDP) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
Total Return (1Y)	13.29%	28.77%
Total Return (3Y, Annualized)	35.26%	37.63%
Total Return (5Y, Annualized)	24.49%	23.78%

Risk Profile

Drawdown History

MEDP

UTHR

GSPC

Medpace (MEDP) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Medpace (MEDP) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
Volatility (1Y, Annualized)	44.16%	35.00%
Beta (5Y)	1.10	0.49
Max Drawdown (5Y)	-42.87%	-33.00%
Avg. Volume (3M)	258.39K	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

MEDP and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
Sharpe Ratio (1Y)	0.20	0.70
Sortino Ratio (1Y)	0.26	1.29

Profitability

ROE (TTM)

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; United Therapeutics (UTHR) at 19.13% also sits in the top quartile.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Medpace (MEDP) at 18.24% and United Therapeutics (UTHR) at 38.61% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Medpace (MEDP) at 23.12% and United Therapeutics (UTHR) at 28.99% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
ROE (TTM)	117.88%	19.13%
ROA (TTM)	18.71%	10.91%
Net Margin (TTM)	18.24%	38.61%
Operating Margin (TTM)	23.12%	28.99%
Gross Margin (TTM)	72.24%	86.34%

Growth

Revenue Growth

Both Medpace (MEDP) at 19.97% and United Therapeutics (UTHR) at 10.61% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Medpace (MEDP) at 20.98% and United Therapeutics (UTHR) at 13.07% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
Revenue Growth (YoY)	19.97%	10.61%
Revenue Growth (3Y CAGR)	20.12%	18.02%
EPS Growth (YoY)	20.98%	13.07%
EPS Growth (3Y CAGR)	28.04%	22.92%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) at 4.61 keeps current ratio within its industry’s typical mid-range, while Medpace (MEDP) at 0.83 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MEDP.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Medpace (MEDP) carries debt-to-equity ratio of 0.29 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Medpace (MEDP) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; MEDP is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
Current Ratio (MRQ)	0.83	4.61
Debt / Equity (MRQ)	0.29	--
Net Debt / EBITDA	-0.84	-1.53

Dividends

Dividend Yield (TTM)

Neither Medpace (MEDP) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Medpace (MEDP) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Medpace (MEDP) at 36.26 and United Therapeutics (UTHR) at 21.22 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Medpace (MEDP) at 6.44 and United Therapeutics (UTHR) at 7.51 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Medpace (MEDP) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Medpace (MEDP) and United Therapeutics (UTHR)
Metric	MEDP	UTHR
P/E Ratio (TTM)	36.26	21.22
P/S Ratio (TTM)	6.44	7.51
P/B Ratio (MRQ)	31.23	3.80
Free Cash Flow Yield (TTM)	2.72%	1.90%